Want to see JP:9987 full AI Analyst Report?
Top Page
Suzuken Co
(9987)
Select Model
Select Model
Rating:75Outperform
Price Target:
¥3,247.00
▼(-36.93% Downside)
Action:Reiterated
Date:09/30/26
Overall score is driven primarily by strong financial quality (especially the very low-leverage balance sheet and improved profitability) and favorable valuation (low P/E and high dividend yield). The score is tempered by uneven cash-flow consistency and a mixed technical picture, with the stock still below its 200-day average and momentum signals largely neutral.
Positive Factors
Very low leverage
Suzuken’s near-zero debt-to-equity profile and zero debt in 2026 reduce financing strain and refinancing exposure. A stable equity base gives the company flexibility to maintain operations, support investment, and withstand earnings volatility without relying heavily on creditors.
Negative Factors
Thin absolute margins
Thin margins leave limited room for execution mistakes, cost increases, or unfavorable product mix changes before profitability is affected. Even with recent improvement, Suzuken’s low-margin distribution model means relatively small operating pressures can have a meaningful impact on earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Suzuken’s near-zero debt-to-equity profile and zero debt in 2026 reduce financing strain and refinancing exposure. A stable equity base gives the company flexibility to maintain operations, support investment, and withstand earnings volatility without relying heavily on creditors.
Read all positive factors
Suzuken Co (9987) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥372.16B
Dividend Yield3.81%
Average Volume (3M)316.36K
Price to Earnings (P/E)10.6
Beta (1Y)0.38
Revenue Growth4.65%
EPS Growth23.21%
CountryJP
Employees12,717
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)271.45
Shares Outstanding144,334,410
10 Day Avg. Volume332,890
30 Day Avg. Volume316,360
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.00
Price to Sales (P/S)0.17
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥7,300.00Price Target Upside41.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)182.88
Revenue Forecast (FY)¥2.59T
Suzuken Co Business Overview & Revenue Model
Company Description
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions....
How the Company Makes Money
Suzuken primarily makes money through the wholesale distribution of pharmaceuticals and other healthcare-related products. Its main revenue stream is sales to dispensing pharmacies and medical institutions, where it earns a gross margin on the pro...
Suzuken Co Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.52T | 2.49T | 2.40T | 2.39T | 2.31T | 2.24T |
| Gross Profit | 192.61B | 192.53B | 192.23B | 185.25B | 179.69B | 167.33B |
| EBITDA | 64.88B | 66.68B | 62.39B | 51.58B | 39.48B | 32.55B |
| Net Income | 37.73B | 38.14B | 34.50B | 29.02B | 20.34B | 14.39B |
Balance Sheet | ||||||
| Total Assets | 1.20T | 1.16T | 1.11T | 1.23T | 1.15T | 1.14T |
| Cash, Cash Equivalents and Short-Term Investments | 148.78B | 141.67B | 141.58B | 242.11B | 192.70B | 201.46B |
| Total Debt | 24.38B | 0.00 | 1.80B | 1.80B | 1.80B | 1.88B |
| Total Liabilities | 779.79B | 739.75B | 706.41B | 812.26B | 734.57B | 723.65B |
| Stockholders Equity | 415.70B | 415.88B | 407.29B | 416.31B | 411.21B | 417.69B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 18.50B | -79.39B | 76.41B | 22.21B | -1.64B |
| Operating Cash Flow | 0.00 | 33.57B | -65.08B | 87.22B | 37.27B | 9.52B |
| Investing Cash Flow | 0.00 | 12.82B | 20.38B | 10.35B | -46.36B | 1.44B |
| Financing Cash Flow | 0.00 | -33.34B | -35.48B | -31.72B | -26.22B | -11.60B |
Suzuken Co Technical Analysis
Positive
5148.00
Price Trends
2590.97
Positive
2542.83
Positive
2749.70
Positive
Market Momentum
66.19
Negative
75.13
Negative
78.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Positive. The current price of 5148 is above the 20-day moving average (MA) of 2665.95, above the 50-day MA of 2590.97, and above the 200-day MA of 2749.70, indicating a bullish trend. The MACD of 66.19 indicates Negative momentum. The RSI at 75.13 is Negative, neither overbought nor oversold. The STOCH value of 78.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9987.
Suzuken Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥372.16B | 10.63 | 9.19% | 3.81% | 4.65% | 23.21% | |
72 Outperform | ¥581.61B | 14.11 | 7.26% | 2.43% | 4.17% | 15.59% | |
69 Neutral | ¥427.47B | 13.59 | 11.15% | 3.61% | 4.32% | 0.18% | |
63 Neutral | ¥459.23B | 11.14 | 7.93% | 2.87% | 4.61% | 43.22% | |
62 Neutral | ¥488.12B | 15.52 | 9.94% | 1.39% | 8.97% | -29.54% | |
56 Neutral | ¥413.54B | 21.70 | ― | 1.81% | 12.54% | 15.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9987
Suzuken Co
2,886.50
-47.91
-1.63%
JP:2784
Alfresa Holdings
2,406.50
253.14
11.76%
JP:7459
Medipal Holdings
3,206.00
658.30
25.84%
JP:9989
Sundrug Co
3,656.00
-430.36
-10.53%
JP:7649
Sugi Holdings Co
1,256.00
-453.69
-26.54%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,325.00
371.08
9.39%
Suzuken Co Corporate Events
Suzuken to Restart Production at Earthquake-Hit Kumamoto Plant
Oct 16, 2026
Suzuken Co. announced that production will resume at the Kumamoto Plant of its pharmaceutical subsidiary Sanwa Kagaku Kenkyusho on October 19, 2026, after operations were suspended due to damage from the July 2026 Kumamoto earthquake. Following ex...
Suzuken Advances Share Buyback Ahead of Two-for-One Stock Split
Oct 1, 2026
Suzuken Co., Ltd. has reported that it repurchased 990,000 of its own common shares in September 2026, at a total cost of approximately ¥5.13 billion. The buyback was executed via the Tokyo Stock Exchange, including the ToSTNeT-3 off-auction ...
Suzuken Sees Silchester Lift Stake to Become Largest Shareholder
Sep 9, 2026
Suzuken Co. has announced a change in its major shareholder and largest shareholder following the submission of a Large Shareholding Change Report by Silchester International Investors LLP. The London-based investment advisory firm increased its h...
Suzuken Advances Capital Policy With Share Buyback Ahead of Stock Split
Sep 3, 2026
Suzuken Co. has executed a share repurchase of 990,000 common shares for a total of approximately 5.13 billion yen at 5,183 yen per share through the ToSTNeT-3 off-auction own share repurchase system on September 3, 2026. The move is part of a bro...
Suzuken Sets ToSTNeT-3 Buyback as Part of Expanded Share Repurchase and Stock Split Plan
Sep 2, 2026
Suzuken Co., Ltd. has approved a specific method to execute part of its previously announced share repurchase program under Article 459, Paragraph 1 of the Companies Act. The company will place a buy order through the Tokyo Stock Exchange’s ...
Suzuken Launches ¥18 Billion Share Buyback Ahead of Stock Split
Aug 28, 2026
Suzuken Co., Ltd. has authorized a new share repurchase program under its Articles of Incorporation, leveraging provisions of Japan’s Companies Act to adjust its capital structure and respond to shifts in the business environment. The initia...
Suzuken Targets October Restart for Quake-Hit SKK Kumamoto Plant, Sees Limited Group Earnings Impact
Aug 28, 2026
Suzuken said its subsidiary Sanwa Kagaku Kenkyusho’s Kumamoto Plant, which was damaged in the July 2026 Kumamoto Earthquake, suffered mainly from impairment to water-supply utilities such as storage tanks and piping, requiring repairs that m...
Suzuken Posts Higher Sales but Profit Decline, Affirms Outlook and Stock Split Plan
Aug 7, 2026
Suzuken reported consolidated net sales of ¥628.9 billion for the quarter ended June 30, 2026, up 6.1% year on year, but operating profit fell 25.0% to ¥4.2 billion and profit attributable to owners of parent declined 10.6% to ¥3.4 ...
Suzuken Assesses Kumamoto Quake Impact as Kumamoto Plant Halts Operations
Jul 30, 2026
Suzuken has activated emergency response headquarters across its group companies following the July 28 Kumamoto Earthquake to verify employee safety and assess operational damage. The company reports that all employees at its affected Kyushu-based...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.